Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

@article{Lebranchu2002ImmunoprophylaxisWB,
  title={Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.},
  author={Yvon Lebranchu and Frank Bridoux and Matthias B{\"u}chler and Yannick Le Meur and Isabelle Etienne and Olivier Toupance and Bruno Hurault de Ligny and Guy Touchard and Bruno Moulin and Patrick Le Pogamp and Olivier Reigneau and M. M. Guignard and G{\'e}rard Rifle},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2002},
  volume={2 1},
  pages={48-56}
}
Acute graft rejection remains a major problem in renal transplant recipients, and there is no consensus on the optimal immunosuppressive strategy. Immunoprophylaxis with Thymoglobulin or basiliximab has significantly reduced the incidence of acute rejection episodes and graft loss following kidney transplantation. This open, randomized, multicenter study investigated the efficacy and tolerability of basiliximab (20mg day 0-day 4) plus early cyclosporine from day 0 (n = 50) compared with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 81 extracted citations

Similar Papers

Loading similar papers…